A clinical trial involving exenatide has been updated to completed status as of September 15, 2026. The study, registered as NCT01988545 and titled "GLP-1's Effect on Cardiac Parameters and Mesenteric Blood Flow," is listed with a phase designation of not applicable.
Exenatide is an approved compound, and this trial examined its relationship to cardiac parameters and mesenteric blood flow. The trial registry record reflects a status change to completed, indicating that the study has concluded its planned activities as of the listed date.
No results or outcome data are included in this update. The completion status refers only to the trial reaching its endpoint in terms of study conduct, not to any specific findings being reported at this time.
Readers interested in additional details can review the official registry entry for further information on study design and any future results postings. For more background on exenatide, see the compound overview linked with this brief.